Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study

Clinical trial NCT06946836 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06946836
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Non-small Cell Lung Cancer Bispecific Antibody Neoadjuvant Therapy

Start date: 2025-04-21
Primary completion: 2031-05-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.